This is a preview of subscription content, log in via an institution to check access.
Notes
including cinoxacin, ciprofloxacin, flumequine, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, pefloxacin, pipemidic acid, prulifloxacin and rufloxacin.
CHMP = Committee for Medicinal Products for Human Use
Reference
European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Internet Document : [3 pages], 16 Nov 2018. Available from: URL: https://www.ema.europa.eu/en/news/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone
Rights and permissions
About this article
Cite this article
EU restrictions for quinolone antibacterials due to serious ADRs. Reactions Weekly 1730, 1 (2018). https://doi.org/10.1007/s40278-018-54901-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-54901-8